FDA urges "black box" warning on pediatric antidepressants

A blue-ribbon scientific advisory panel has urged the US Food and Drug Administration (FDA) to include “black box” warnings on selective serotonin reuptake inhibitors (SSRIs) advising of the increased risk of suicidal behaviour among pediatric users. Black box warnings are typically reserved for